Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint
ARGX•Phase 3 Alkivia trial met primary endpoint
Aug. 17 (Reuters) - argenx SE ARGX.BR:
- Argenx announces positive topline results from Phase 3 Alkivia trial of efgartigimod in autoimmune myositis
- Phase 3 study meets primary endpoint in IMNM and DM patients at week 52
- Efgartigimod demonstrates early and sustained improvement over placebo through one year
- Efgartigimod well-tolerated with consistent safety profile in Alkivia study
